Ascendis Pharma has granted Novo Nordisk an exclusive worldwide license for its TransCon technology platform to develop treatments for metabolic and cardiovascular diseases. This strategic partnership will focus on developing long-acting treatments for obesity, type 2 diabetes, and other cardiovascular conditions.